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Background: The 7th edition of the International Union Against Cancer/American Joint Committee on
Cancer (UICC/AJCC) tumor-node-metastasis (TNM) classiﬁcation system for gastric cancer is more
detailed than the 6th edition with respect to tumor depth and lymph node metastasis. The purpose of
this study was to evaluate the rationality of the 7th UICC/AJCC TNM classiﬁcation system, focusing on N3
gastric cancers.
Methods: A total of 338 patients with N3 gastric cancer who underwent curative resection with 16
retrieved lymph nodes at two institutions between January 1997 and December 2007 were included in
this study. Patients were divided into the N3a (n ¼ 210) and N3b (n ¼ 128) groups. Clinicopathologic
characteristics and survival rates were compared between groups.
Results: No difference in clinicopathologic characteristics, including age (p ¼ 0.989), sex (p ¼ 0.382),
tumor location (p ¼ 0.124), surgery type (p ¼ 0.909), depth of invasion (p ¼ 0.313), histologic type
(p ¼ 0.111), and Lauren classiﬁcation (p ¼ 0.491), was observed between patients with N3a and N3b
gastric cancer. However, overall survival (OS) rates of patients with N3a gastric cancer were greater than
that of patients with N3b gastric cancer (5-year OS, 46% vs. 28%; 10-year OS, 33% vs. 19%; both p < 0.001).
Five-year survival rates differed signiﬁcantly between patients with T3N3a and T3N3b (p ¼ 0.006) sub-
stages and between those with T4aN3a and T4aN3b (p ¼ 0.004) sub-stages.
Conclusions: The results of this study support N3 sub-classiﬁcation for gastric cancers, which warrant
differential consideration according to TNM stage.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Incheon St. Mary's Hospital,
Korea, 665, Bupyung-dong,
).
by Elsevier Ltd. All rights reserved1. Background
Gastric cancer (GC) remains the fourth most common cancer
worldwide and the second leading cause of cancer-related deaths
[1]. The tumor-node-metastasis (TNM) staging system provides a
standard used to classify the anatomic extent of disease, predict
prognosis, determine a treatment plan, and facilitate the exchange
of information [2]. The staging system is revised periodically, and.
Table 1
Patient characteristics.
Characteristics N3a (n ¼ 210) N3b (n ¼ 128) P value
Age (year)
Mean ± SDa 59.9 ± 12.13 59.6 ± 11.36 P ¼ 0.989
Gender
Male:Female (ratio) 152:58 (2.6:1) 85:43 (2.0:1) P ¼ 0.382
Location
Upper 27 15 P ¼ 0.124
Middle 43 37
Lower 137 71
Whole 3 5
Type of surgery
Distal gastrectomy 126 78 P ¼ 0.909
Total gastrectomy 84 50
Depth of invasion
T1 8 2 P ¼ 0.313
T2 19 7
T3 48 36
T4a 126 74
T4b 9 9
Differentiation
Differentiatedb 80 35 P ¼ 0.111
Undifferentiatedc 116 85
Unknown 14 8
Lauren classiﬁcation
Intestinal 85 56 P ¼ 0.491
Diffuse 62 29
Mixed 45 28
Unknown 18 15
a SD: standard deviation.
b Differentiated: papillary, well, and moderately differentiated.
c Undifferentiated: poorly differentiated, mucinous, and signet ring cell
carcinoma.
Table 2
Stage migration.
Tumor depth Involved node
N3a (7e15) N3b (16)
6th Stage 7th Stage 6th Stage 7th Stage
T1 (a/b) II (8) IIB (8) IV (128) IIB (2)
T2 IIIA (67) IIIA (19) IIIA (7)
T3 IIIB (48) IIIB (36)
T4a IIIB (126) IIIC (135) IIIC (83)
T4b IV (9)
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Joint Committee on Cancer (UICC/AJCC) TNM classiﬁcation system
for GC was published in 2010. Although this staging system con-
tinues to use N classiﬁcations based on the absolute number of
regional lymph node metastases, the revisions incorporated in the
7th edition permit more detailed staging in terms of depth of in-
vasion (T), regional lymph node metastasis (N), and distant
metastasis (M) compared with the 6th edition. The 7th edition of
the TNM staging system redeﬁnes N stages: patients with 1e6
regional lymph node metastases are divided into stages N1 and N2
(corresponding to the N1 stage of the 6th edition), those with 7e15
such metastases are classiﬁed as stage N3a (N2 in the 6th edition),
and patients with >15 regional lymph node metastases are classi-
ﬁed as stage N3b. The 7th edition of UICC TNM stage does sub-
classify the N3 classiﬁcation into N3a and N3b but this does not
inﬂuence the ﬁnal stage of the disease. Several investigators have
proposed that the 7th-edition N3 classiﬁcation be sub-classiﬁed as
N3a and N3b to permit more accurate prediction of cancer prog-
nosis [3,4]. However, the evidence supporting the necessity and
rationality for N3 sub-classiﬁcation is insubstantial. The purpose of
this study was to evaluate the effectiveness of the 7th edition of the
TNM staging system focusing on N3 GCs.
2. Methods
2.1. Patients
Between January 1997 and December 2007, 382 patients with
N3 gastric adenocarcinoma underwent gastrectomy at two in-
stitutions. Data from these patients were entered into a prospec-
tively maintained database. The Institutional Review Boards
approved the study protocol (no. OC12RISE0127) (no.
VC13RIMI0122). All the enrolled patients had the following curative
aim for their operative procedures: 1) total or subtotal gastrectomy
depending on the location and 2) D2 or higher lymphadenectomy.
Exclusion criteria for this study were (1) non-curative resection, (2)
multiple primary malignancies, (3) remnant GC, (4) 15 retrieved
lymph nodes, and (5) mortality within 30 days after surgery. After
the application of these criteria, 338 patients were included in the
current study. Data from these patients were re-evaluated using the
7th edition of the UICC/AJCC TNM classiﬁcation system.
The patients comprised 237 males and 101 females with a mean
age of 59.7 (range, 29e89) years. Tumors were located in the upper
third of the stomach in 42 (12.4%) patients, the middle third in 80
(23.7%) patients, the lower third in 208 (61.5%) patients, and the
entire stomach in 8 (2.4%) patients. Two hundred and four (60.4%)
and 134 (39.6%) patients underwent subtotal and total gastrec-
tomies, respectively. Histologically, undifferentiated cancers
(n ¼ 201) were more common than differentiated types (n ¼ 115).
According to the depth of invasion, the numbers of patients with
stages T1b, T2, T3, T4a, and T4b were 10, 26, 84, 200, and 18,
respectively. Two hundred and ten patients had stage N3a and 128
patients had stage N3b GC. Clinical and pathologic characteristics
and survival rates were compared among patients with groups N3a
and N3b GC. The patients were followed for a median of 45 (range,
1.4e187.1) months. Patient information was obtained from our
database and that of the Korea Central Cancer Registry.
2.2. Statistical analysis
The study endpoint was overall survival deﬁned as the time
from the date of surgery to the date of death or last follow-up
evaluation. Overall survival rates were compared between the
N3a and N3b groups. We used the chi-squared or Fisher's exact test
for all analyses except the comparison of age, which was performedusing the ManneWhitney U-test. Overall survival rates were
calculated using the KaplaneMeier method, and the log-rank test
was employed to determine the signiﬁcance of differences
(p < 0.05).3. Results
The clinicopathologic characteristics of the 338 patients with N3
GC are summarized in Table 1. No difference in these characteristics,
including age (p ¼ 0.989), sex (p ¼ 0.382), tumor location
(p ¼ 0.124), surgery type (p ¼ 0.909), depth of invasion (p ¼ 0.313),
histologic type (p ¼ 0.111), and Lauren classiﬁcation (p ¼ 0.491),
was observed between patients with N3a and N3b GC.
Differences in staging according to the 6th and 7th editions of
the TNM system are shown in Table 2. Among patients with N3a GC,
those classiﬁed as stage IIIA (n ¼ 67) according to the 6th edition
were re-classiﬁed as stages IIIA (n ¼ 19) and IIB (n ¼ 48) according
to the 7th edition. Patients classiﬁed as stages IIIB (n ¼ 126) and IV
(n ¼ 9) according to the 6th edition were re-classiﬁed as the new
uniﬁed stage IIIC (n ¼ 135) according to the 7th edition. Patients
classiﬁed as stage IV (n¼ 128) according to the 6th editionwere re-
Table 3
The proposal TNM stage groups of pN3 gastric cancer.
7th Stage Proposal TNM stage
N3 (a/b) N3a N3b
T3 IIIB T3 T3N3a T3N3b
T4a IIIC T4a T4aN3a T4aN3b
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(n ¼ 83) according to the more detailed system of the 7th edition.
Little difference in survival rates among the stages of each system
were observed, presumably due to the small number of patients
assigned to each stage (data not shown).
The 5-year and 10-year overall survival rates of patients with N3
GC were 39% and 28%, respectively. These rates were higher in the
N3a group than in the N3b group (5-year survival, 46% vs. 28%; 10-
year survival, 33% vs. 19%; both p < 0.001; Fig. 1).
We re-classiﬁed stage T3N3 (IIIB) as T3N3a and T3N3b and stage
T4aN3 (IIIC) as T4aN3a and T4aN3b (Table 3). Five-year survival
rates for these proposed staging groups differed signiﬁcantly be-
tween T3N3a and T3N3b (45% vs. 24.7%; p ¼ 0.006; Fig. 2A) and
between T4aN3a and T4aN3b (43.5% vs. 22.9%; p ¼ 0.004; Fig. 2B).4. Discussion
Despite its declining global incidence, GC remains one of the
most common malignancies in the world [1]. Half of all cases
worldwide occur in East Asia [5]. In South Korea, GC is now the
most prevalent malignant neoplasm, affecting >25,000 patients
annually. It is also the second leading cause of cancer deaths after
lung cancer and is responsible for >10,000 deaths per year [6].
Approximately 15,000 patients with GC undergo gastrectomy every
year, excluding endoscopic resection, bypass surgery, and explor-
atory surgery. R0 curative resection was achieved in 92.4% of cases,
with a mean of 38 retrieved lymph nodes [7].
The TNM classiﬁcation is used worldwide for GC staging in
clinical practice and research. Accurate staging is critical for pre-
dicting disease recurrence and survival, determining adjuvant
treatment strategies, and comparing oncologic outcomes across
institutions. Since the publication of the ﬁrst edition in the 1960s,
the UICC/AJCC TNM staging system has been revised several times
[8e10]. In the 5th edition, nodal staging was based on the number
of metastatic lymph nodes [9]. The 6th edition was published inFig. 1. Overall survival rates of patients with N3 gastric cancer.2009, and revisions incorporated in the 7th edition, published in
2010, enable even more detailed staging. The development of an
appropriate lymph node staging system for GC has been contro-
versial, involving frequent changes with proposed amendments to
the TNM classiﬁcation system [11e13]. In particular, the N classi-
ﬁcation used in the 7th edition requires careful consideration and
discussion. In this edition, N classiﬁcation has been redeﬁned based
on the absolute number of regional lymph node metastases, and
pathologic assessment of 16 regional lymph nodes is recom-
mended. The extent of lymph node dissection can inﬂuence nodal
staging by affecting the number of lymph nodes examined patho-
logically, potentially leading to the stage reassignment of patients
[14,15]. We enrolled in this study only patients who underwentFig. 2. Five-year survival rates according to proposed TNM staging for patients with
(A) T3N3a versus T3N3b and (B) T4aN3a versus T4aN3b gastric cancer.
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population was useful for the comparisons of staging according to
different classiﬁcation systems and evaluation of the prognostic
impact of lymph node dissection according to nodal staging.
In the 7th edition of the TNM classiﬁcation system, stage N3 is
sub-categorized as N3a and N3b, but this sub-classiﬁcation is not
used for ﬁnal staging. Stage N3b (IV in 6th edition) appears to be an
important prognostic determinant that we propose should be
regarded as a highly advanced stage. To enable such consideration,
we sub-classiﬁed stage T3N3 into T3N3a and T3N3b and stage
T4aN3 into T4aN3a and T4aN3b. Using this proposed TNM system,
we found that 5-year survival rates differed signiﬁcantly between
patients with stage T3N3a and T3N3b and those with stage T4aN3a
and T4aN3b GC. The results of this study support those of a pre-
vious study, which reported a signiﬁcant difference in survival rate
between patients with stages N2 and N3 (6th edition) GC [16,17]. Li
et al. [4] also emphasized the illogicality of the 7th edition N3
classiﬁcation system and the need to deﬁne N3 sub-stages (N3a and
N3b). Dikken et al. [18] reported that overall stage-speciﬁc pre-
dictive accuracy was not improved in the 7th edition, and recom-
mended an amended staging system with enhanced prognostic
accuracy. Jung et al. [19] indicated that the low discriminative po-
wer of the N1 and N2 classiﬁcations may result in unnecessary
stage reassignment, and that the N3 classiﬁcation, which does not
distinguish between N3a and N3b, certainly lowers the predicted
relative risk in advanced N stage disease. Kim et al. [3] reported that
the survival rate of patients with stage IIIC GC and >29 metastatic
lymph nodes did not differ from that of patients with stage IV GC,
and proposed this number of metastatic lymph nodes as a cutoff
value for N classiﬁcation.
This study has several limitations. First, the number of subjects
was insufﬁcient for detailed staging validation. Although most
staging groups were represented by >15 patients, the stage IIB
group comprised only 10 patients. Second, as this study population
was representative of patients from only two Korean institutions,
multinational validation of the proposed TNM staging system is
needed. Despite these limitations, this study has considerable
clinical signiﬁcance, as the surgical procedures, pathologic exami-
nations, and follow-up protocol were consistent throughout the
study period.5. Conclusions
In conclusion, the nodal sub-classiﬁcation into N3a and N3b is
present but does not translate into a change in ﬁnal TNM stage. The
proposed sub-classiﬁcation of N3a and N3b GCs permits differential
consideration of patients with these sub-stage assignments.
Because of the limitations of retrospective analyses and patient
selection bias, a multinational validation study is needed to reach
deﬁnitive conclusions.Ethical approval
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